資料搜尋諮詢服務
找不到您所需要的資料嗎?
我們能協助您找到最符合您研究需求的資訊
請撥打 +886-2-2799-3110
或透過電子郵件與我們聯絡 mi@hintoninfo.com
IHS_EWBIEEE xploreSTRATEGY ANALYTICSELSEVIERIHS_EWB_GF

頁面路徑選單

最新消息http://www.hintoninfo.com.tw/

2020/04/09 COVID-19: Analysis of the Emerging Disease Landscape – March 2020

 A range of players – from pharma & biotech firms to academic institutions & government agencies – have thrown their hats in the ring.

COVID-19: Analysis of the Emerging Disease Landscape

The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. 


Single User License: $2,495

Report format: PPT

In rare instances, coronavirus variants have been known to cause severe disease in humans. There are three such cases: severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19.


The COVID-19 therapeutic pipeline consists of 89 drugs spanning all stages of development (discovery to Phase III); 16 of these drugs have reached clinical-stage development, Phases I–III. The pipeline is largely in the early stage, with approximately 69% of the drugs in discovery and preclinical phases.

The lack of a vaccine means that the outbreak has spread nearly unabated, slowed only by such prevention measures as social distancing without the benefit of any vaccine-conferred immunity in the population.

For patients diagnosed with COVID-19, the unavailability of any treatments proven to be efficacious in relieving symptoms and treating the underlying disease means that supportive care is the only therapeutic option.

Report Scope:

  • Global epidemiology metrics and trends - Snapshot of epidemiological trends to date in the top three most-affected countries
  • An overview of the pipeline for antivirals and vaccines
  • Summary of available efficacy data
  • An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
  • Highlights in deal-making trends, particularly public-private partnerships
回上頁